Product Center
Recombinant Herpes Zoster Vaccine (CHO Cell) IND Application Accepted
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-02-23
- Views:
(Summary description)On February 23, 2024, Ab&B Bio Tech Co., Ltd. JS independently developed a Class I new drug, the recombinant herpes zoster vaccine (CHO cell), whose IND application was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Recombinant Herpes Zoster Vaccine (CHO Cell) IND Application Accepted
(Summary description)On February 23, 2024, Ab&B Bio Tech Co., Ltd. JS independently developed a Class I new drug, the recombinant herpes zoster vaccine (CHO cell), whose IND application was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-02-23 16:13
- Views:
Herpes zoster (HZ) is an infectious disease that mainly affects nerves and skin, caused by reactivation of the varicella-zoster virus (VZV). Its main characteristics are clustered blisters distributed in a stripe-like pattern, accompanied by significant neuralgia. The older the age, the more severe the neuralgia. This disease is common in older adults, immunocompromised individuals, and those using immunosuppressants, and has a certain recurrence rate. Currently, there is no effective treatment for herpes zoster, and vaccination is the most effective means of prevention.
Ab&B Bio Tech Co., Ltd. JS adheres to the principle of avoiding simple replication and focuses on independent innovation in research and development. The recombinant herpes zoster vaccine (CHO cells) accepted this time utilizes multiple independent intellectual property innovations, adjuvant systems, and an officially authorized high-expression cell matrix from the company. Preclinical studies have shown that this product can simultaneously induce high levels of specific antibodies and CD4+ T-cell responses, demonstrating high immunogenicity, efficacy, and safety.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
